No Data
No Data
Reviva Pharm Holdings Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
Express News | Reviva Granted A European Patent Covering The Use Of Brilaroxazine In Treatment Of Pulmonary Hypertension
Express News | Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $14 Price Target
H.C. Wainwright Maintains Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Cuts Target Price to $14
Reviva Pharm Holdings Is Maintained at Buy by HC Wainwright & Co.